ProLingua RX: Language communication tool for pharmacists (Phase II)

ProLingua RX：药剂师语言交流工具（第二阶段）

• 批准号: 7220093
• 负责人: Chung-Suk Charles Lee
• 金额: $ 39.19万
• 依托单位: POLYGLOT SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2009-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7220093
• 关键词: Accounting; Applications Grants; Budgets; Cessation of life; Communication Tools; Computers; Daily; Data Set; Databases; Development; English Language; Goals; Home environment; Injury; Institute of Medicine (U.S.); Institution; Instruction; Internet; Koreans; Language; Letters; Link; Medication Errors; Medicine; Methods; Online Systems; Patients; Pharmaceutical Preparations; Pharmacists; Pharmacy Schools; Pharmacy facility; Phase; Population; Progress Reports; Sales; Schedule; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Solutions; System; Techniques; Technology; Time; Translating; Translations; United States; Visual; Writing; base; concept; cost; foreign language; health care delivery; health disparity; health literacy; innovation; prescription document; prescription procedure; prototype; response

DESCRIPTION (provided by applicant): ProLingua RX: Language communication tool for pharmacists. Twenty million people in the United States are unable to speak an effective level of the English language to understand simple medicine instructions. This Limited English Proficient (LEP) population represents 1 of every 15 people in the United States. This population is expected to increase 40% over the next 20 years. The Institute of Medicine (IOM) estimates that medication errors account for about 7,000 deaths annually and costs approximately $2 billion for the nation as a whole. Medication errors were also found to account for over 700,000 injuries each year. Language barrier has been found to be a significant cause of some of these deaths and injuries. During Phase I we developed an innovative system for professional pharmacists to generate medicine instructions in a foreign language, provide these instructions to LEP patients in both written and verbal form, and demonstrate proper techniques for medication use. During Phase II we will expand upon this system by incorporating 6 foreign languages (Spanish, Korean, Mandarin, Russian, Vietnamese, and Arabic), adding the top 300 prescriptions to our medicine database, creating 50 new medicine demonstrations, and developing a system to enable access to these instructions from any remote computer through the Internet. The goal of this Phase II grant application is to develop a commercial, technology-based, time-saving solution to help every pharmacist articulate and visually demonstrate medications instructions to their patients regardless of language barrier. This solution has the potential to significantly reduce medication errors and health disparity due to language barriers as well as low health literacy, while reducing cost of healthcare delivery in the United States.

描述（由申请人提供）： ProLingua RX：药剂师的语言交流工具。美国有 2000 万人无法使用有效的英语水平来理解简单的医学说明。美国每 15 人中就有 1 人属于英语水平有限 (LEP) 人群。未来 20 年，这一人口预计将增加 40%。美国医学研究所 (IOM) 估计，用药错误每年导致约 7,000 人死亡，给整个国家造成约 20 亿美元的损失。研究还发现，用药错误每年造成超过 700,000 起伤害。人们发现，语言障碍是造成部分死亡和受伤的一个重要原因。在第一阶段，我们为专业药剂师开发了一个创新系统，用外语生成药物说明，以书面和口头形式向 LEP 患者提供这些说明，并演示正确的用药技术。在第二阶段，我们将扩展该系统，纳入 6 种外语（西班牙语、韩语、普通话、俄语、越南语和阿拉伯语），将前 300 个处方添加到我们的药物数据库中，创建 50 个新药物演示，并开发一个系统允许通过互联网从任何远程计算机访问这些指令。第二阶段拨款申请的目标是开发一种基于技术的商业、节省时间的解决方案，以帮助每位药剂师向患者清晰地表达和直观地展示药物说明，而无需考虑语言障碍。该解决方案有可能显着减少由于语言障碍和健康素养低下而导致的用药错误和健康差异，同时降低美国的医疗保健服务成本。